What's Next For Bristol's Opdivo/Yervoy Combination
Executive Summary
Updated data from CheckMate 012 of Yervoy/Opdivo in first-line lung cancer bode well for the Phase III CheckMate 227 study, plus other indications, Bristol says.
You may also be interested in...
Another Opdivo Disappointment For BMS, This Time In Kidney Cancer
Bristol-Myers Squibb's Opdivo plus Yervoy in first-line RCC did not achieve statistical significance in terms of progression-free survival versus Sutent, but overall survival data aren't available yet.
Bristol's Oncology Strategy: Cover All The Bases To Keep The Lead
Bristol stresses comprehensive approach to lung cancer – its top priority – with trials from early to late stages, a thoughtful biomarker development program and a pipeline stocked with drugs that have a wide range of targets.
Merck Poised To Be First To Market With A PD-1 For First-Line Lung Cancer
Merck’s Keytruda improved progression-free survival and overall survival in previously untreated non-small cell lung cancer patients in the highly-anticipated KEYNOTE-024 trial, all but guaranteeing a rapid FDA approval in the indication.